Prophylactic Azithromycin for Bronchiectasis, a randomised controlled trial to assess whether azithromycin reduces exacerbation frequency, improves health-related quality of life and increases lung function.

Not Applicable

Completed

• Conditions: Bronchiectasis; Respiratory - Other respiratory disorders / diseases

• Registration Number: ACTRN12607000641493
• Lead Sponsor: Centre for Clinical Research and Effective Practice (CCRep)

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2007-12-17
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 140

Inclusion Criteria

1. Participants must have a diagnosis of bronchiectasis based on a high resolution Computer Tomography (CT) scan
2. Patient must be clinically stable during the baseline period
3. Patient must have at least one exacerbation in the last 12 months requiring treatment with antibiotics.

Exclusion Criteria

1. Patient with significant diseases other than bronchiectasis
2. Patient with cystic fibrosis
3. Patient with hypogammaglobulinaemia
4. Patients with primary dyskinesia
5. Patients with allergic brochopulmonary aspergillosis
6. Patients with non-tuberculous mycobacterial infection within 2 years.
7. Patients with a malignancyrequiring treatment in the last 5 years (patients with basal cell carcinoma are allowed)
8. Patients with active tuberculosis.

Study & Design

• Study Type: Interventional
• Study Design: Not specified